Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report) shares traded down 2.5% during trading on Monday . The company traded as low as $2.66 and last traded at $2.74. 84,282 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 124,099 shares. The stock had previously closed at $2.81.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. HC Wainwright decreased their price target on Inhibikase Therapeutics from $15.00 to $5.00 and set a "buy" rating for the company in a report on Monday, October 14th. Jefferies Financial Group began coverage on shares of Inhibikase Therapeutics in a research note on Friday, November 8th. They issued a "buy" rating and a $8.00 target price for the company.
Check Out Our Latest Report on IKT
Inhibikase Therapeutics Stock Performance
The stock has a market cap of $146.70 million, a PE ratio of -0.79 and a beta of 1.11. The company has a 50 day moving average of $2.96 and a two-hundred day moving average of $2.11.
Inhibikase Therapeutics Company Profile
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Recommended Stories
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
